Program
pertuzumab
Also written as “Pertuzumab”, “Pertuzumab IV” and “Perjeta”.
Its studies are mostly in Breast Neoplasms · Ovarian Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Prostatic Neoplasms, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 411 open or running | phase 4since May 13, 2015 | Nov 15, 2001 | Mar 28, 2027phase 3 · NCT02320435 |
| Cinnagen | 10 open or running | phase 3since Jun 22, 2021 | Jun 22, 2021 | none ahead |
| CSPC Pharmaceutical Group | 11 open or running | phase 3since Nov 25, 2022 | Nov 25, 2022 | none ahead |
| Mabscale | 11 open or running | phase 1since Apr 11, 2023 | Apr 11, 2023 | none ahead |
| Sarah Cannon Research Institute | 10 open or running | phase 2since Aug 27, 2014 | Aug 27, 2014 | none ahead |
| Zydus Lifesciences | 10 open or running | phase 3since Feb 26, 2022 | Feb 26, 2022 | none ahead |
Also a collaborator on its studies: Daiichi Sankyo and roche-pharma-ag.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 33 studies since Nov 15, 2001.
- Aug 10, 2015Phase 2 study in Breast NeoplasmsHoffmann-La Roche · NCT02536339 · 40 enrolled · United States
- Oct 23, 2015Phase 3 study in Breast NeoplasmsHoffmann-La Roche · NCT02586025 · 329 enrolled · China, Korea, Republic of, Taiwan and more
- Mar 29, 2016Phase 1 study in Breast NeoplasmsHoffmann-La Roche · NCT02738970 · 88 enrolled · New Zealand
- Sep 7, 2016Phase 3 study in Breast NeoplasmsHoffmann-La Roche · NCT02896855 · 243 enrolled · China
- Apr 4, 2018Phase 3 study in Breast NeoplasmsHoffmann-La Roche · NCT03493854 · 500 enrolled · United States, Argentina, Belgium and more
- Apr 5, 2018Phase 2 study in Neoplasms, Unknown PrimaryHoffmann-La Roche · NCT03498521 · 529 enrolled · Australia, Austria, Brazil and more
- Sep 12, 2018Phase 2 study in HER2-Positive Early Breast CancerHoffmann-La Roche · NCT03674112 · 160 enrolled · United States, Argentina, Brazil and more
- Jul 17, 2019Phase 3 study in HER2-positive Early Breast CancerHoffmann-La Roche · NCT04024462 · 200 enrolled · China
- Jun 22, 2021Cinnagen's first study: phase 3 study in HER2-positive Breast CancerNew to CinnagenCinnagen · NCT04957212 · 214 enrolled · Iran, Islamic Republic of
- Feb 26, 2022Zydus Lifesciences's first study: phase 3 study in Breast NeoplasmsNew to Zydus LifesciencesZydus Lifesciences · NCT05283837 · 268 enrolled · India
- Jun 8, 2022Phase 3 study in Breast NeoplasmsHoffmann-La Roche · NCT05415215 · 346 enrolled · Argentina, Bosnia and Herzegovina, Brazil and more
- Nov 25, 2022CSPC Pharmaceutical Group's first study: phase 3 study in HER2-positive Breast CancerNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT05720026 · 560 planned · China
- Apr 11, 2023Mabscale's first study: phase 1 study in Healthy MenNew to MabscaleMabscale · NCT05825781 · 114 enrolled · Russian Federation
- Nov 6, 2026Primary completion moved from 2026-12-31 to 2027-03-28Date moved laterphase 3 · +3 months · NCT02320435
Ahead
- Mar 28, 2027Primary completion: phase 3 study in Solid TumorsHoffmann-La Roche · NCT02320435
TargetBeta
“A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
All 46 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05825781Healthy Men · Russian Federation | 1 | Active, not recruiting | Mabscale | Jan 22, 2024 | 114 |
| NCT05720026HER2-positive Breast Cancer · China | 3 | Recruiting | CSPC Pharmaceutical Group | Aug 29, 2025 | 560 |
| NCT05415215Breast Neoplasms · Argentina, Bosnia and Herzegovina, Brazil and more | 3 | Completed | Hoffmann-La Roche | Nov 20, 2024 | 346 |
| NCT05283837Breast Neoplasms · India | 3 | Completed | Zydus Lifesciences | Sep 6, 2023 | 268 |
| NCT04957212HER2-positive Breast Cancer · Iran, Islamic Republic of | 3 | Completed | Cinnagen | May 27, 2020 | 214 |
| NCT04024462HER2-positive Early Breast Cancer · China | 3 | Completed | Hoffmann-La Roche | Dec 13, 2021 | 200 |
| NCT03674112HER2-Positive Early Breast Cancer · United States, Argentina, Brazil and more | 2 | Completed | Hoffmann-La Roche | Feb 24, 2020 | 160 |
| NCT03498521Neoplasms, Unknown Primary · Australia, Austria, Brazil and more | 2 | Completed | Hoffmann-La Roche | Feb 14, 2023 | 529 |
| NCT03493854Breast Neoplasms · United States, Argentina, Belgium and more | 3 | Completed | Hoffmann-La Roche | Jul 4, 2019 | 500 |
| NCT02896855Breast Neoplasms · China | 3 | Completed | Hoffmann-La Roche | Jun 27, 2018 | 243 |
| NCT02738970Breast Neoplasms · New Zealand | 1 | Completed | Hoffmann-La Roche | May 31, 2018 | 88 |
| NCT02586025Breast Neoplasms · China, Korea, Republic of, Taiwan and more | 3 | Completed | Hoffmann-La Roche | Oct 23, 2017 | 329 |
| NCT02536339Breast Neoplasms · United States | 2 | Completed | Hoffmann-La Roche | May 1, 2019 | 40 |
| NCT02507375Carcinoma, Non-Small-Cell Lung · Belgium, Spain, United Kingdom | 1 | Completed | Hoffmann-La Roche | Dec 2008 | 17 |
| NCT02494596Solid Tumor · Spain, United Kingdom | 1 | Completed | Hoffmann-La Roche | Sep 2005 | 19 |
| NCT02490475Solid Tumor · Netherlands, United Kingdom | 1 | Completed | Hoffmann-La Roche | Apr 2006 | 19 |
| NCT02491892Breast Neoplasms · Australia, Belgium, Finland and more | 2 | Completed | Hoffmann-La Roche | Apr 2005 | 79 |
| NCT02480010Prostatic Neoplasms · France, Germany, Italy and more | 2 | Terminated | Hoffmann-La Roche | Sep 2005 | 68 |
| NCT02445586Breast Neoplasms · India | 4 | Completed | Hoffmann-La Roche | Sep 26, 2018 | 52 |
| NCT02320435Solid Tumors · Brazil, China, Costa Rica and more | 3 | Active, not recruiting | Hoffmann-La Roche | Mar 28, 2027 | 154 |
| NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more | 2 | Completed | Hoffmann-La Roche | May 31, 2019 | 1,044 |
| NCT02229149Breast Neoplasms · United States | 2 | Terminated | Sarah Cannon Research Institute | Jan 2022 | 33 |
| NCT02132949Breast Neoplasms · United States, Canada, Denmark and more | 2 | Completed | Hoffmann-La Roche | Mar 3, 2016 | 401 |
| NCT02091141Neoplasms · United States | 2 | Completed | Hoffmann-La Roche | May 24, 2023 | 673 |
| NCT02004093Ovarian Neoplasms · Belgium, Canada, Hungary and more | 2 | Completed | Hoffmann-La Roche | Sep 2008 | 149 |
| NCT01774786Stomach Neoplasms · United States, Australia, Austria and more | 3 | Completed | Hoffmann-La Roche | Dec 9, 2016 | 780 |
| NCT01684878Ovarian Neoplasms · Austria, Belgium, Denmark and more | 3 | Completed | Hoffmann-La Roche | Jan 30, 2015 | 208 |
| NCT01674062Breast Neoplasms · Canada, France, Italy and more | 2 | Completed | Hoffmann-La Roche | Feb 2008 | 95 |
| NCT01572038Breast Neoplasms · Algeria, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Sep 20, 2019 | 1,436 |
| NCT01565083Breast Neoplasms · United States, Brazil, Denmark and more | 2 | Completed | Hoffmann-La Roche | Oct 2015 | 213 |
| NCT01491737Breast Neoplasms · United States, Brazil, France and more | 2 | Completed | Hoffmann-La Roche | Mar 17, 2016 | 258 |
| NCT01461057Stomach Neoplasms · Belgium, Czechia, France and more | 2 | Completed | Hoffmann-La Roche | Mar 1, 2015 | 30 |
| NCT01358877Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Dec 19, 2016 | 4,804 |
| NCT01120184Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Sep 30, 2014 | 1,095 |
| NCT01026142Breast Neoplasms · Argentina, Austria, Belgium and more | 3 | Completed | Hoffmann-La Roche | May 29, 2015 | 452 |
| NCT00976989Breast Neoplasms · Bahamas, Bosnia and Herzegovina, Brazil and more | 2 | Completed | Hoffmann-La Roche | Jun 2011 | 225 |
| NCT00875979Breast Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Hoffmann-La Roche | Aug 2011 | 67 |
| NCT00855894Carcinoma, Non-Small-Cell Lung · United States, Australia | 2 | Completed | Hoffmann-La Roche | Mar 2012 | 41 |
| NCT00567190Breast Neoplasms · United States, Argentina, Brazil and more | 3 | Completed | Hoffmann-La Roche | May 13, 2011 | 808 |
| NCT00545688Breast Neoplasms · Australia, Austria, Brazil and more | 2 | Completed | Hoffmann-La Roche | Sep 22, 2014 | 417 |
| NCT00096993Ovarian Neoplasms · United States | 2 | Completed | Hoffmann-La Roche | Sep 2007 | 131 |
| NCT00096941Solid Cancers | 2 | Completed | Hoffmann-La Roche | Oct 2007 | 3 |
| NCT00063154Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Hoffmann-La Roche | Apr 2005 | 51 |
| NCT00058552Ovarian Neoplasms | 2 | Completed | Hoffmann-La Roche | Jul 2004 | 129 |
| NCT00058539Prostatic Neoplasms | 2 | Completed | Hoffmann-La Roche | Oct 2004 | 42 |
| NCT00027027Neoplasms · United States | 1 | Completed | Hoffmann-La Roche | Aug 2003 | 21 |
How it is read
Names in the registry
- “Pertuzumab”, 36 entries
- “Pertuzumab IV”, 4 entries
- “Perjeta”, 3 entries
- “pertuzumab”, 2 entries
- “RhuMab 2C4”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 34 studies
- Ovarian Neoplasms, 4 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Stomach Neoplasms, 2 studies
- Prostatic Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.